scispace - formally typeset
E

Ella Magal

Researcher at Amgen

Publications -  23
Citations -  1197

Ella Magal is an academic researcher from Amgen. The author has contributed to research in topics: Glial cell line-derived neurotrophic factor & Spiral ganglion. The author has an hindex of 15, co-authored 23 publications receiving 1172 citations.

Papers
More filters
Journal ArticleDOI

Guinea pig auditory neurons are protected by glial cell line-derived growth factor from degeneration after noise trauma

TL;DR: The results demonstrate that GDNF is likely to be an endogeneous survival factor in the normal mammalian cochlea and it could have application as a pharmacological treatment to prevent secondary auditory nerve degeneration following organ of Corti damage.
Journal ArticleDOI

Spiral ganglion neurons are protected from degeneration by GDNF gene therapy.

TL;DR: Adenoviral-mediated GDNF transgene expression enhanced SGC survival in the left (viral-treated) deafened ears, suggesting that GDNF is one of the survival factors in the inner ear and may help maintain the auditory neurons after insult.
Journal ArticleDOI

Hair Cell Protection from Aminoglycoside Ototoxicity by Adenovirus-Mediated Overexpression of Glial Cell Line-Derived Neurotrophic Factor

TL;DR: The results demonstrate the feasibility of gene therapy for cochlear application and suggest that virus-mediated overexpression of GDNF may be developed as a valuable prevention against trauma-induced HC death.
Journal ArticleDOI

Rescue and regrowth of sensory nerves following deafferentation by neurotrophic factors.

TL;DR: Study in the cochlea show that application of exogenous neurotrophic factors can enhance survival of spiral ganglion cells after deafness and induce regrowth of peripheral processes, perhaps by replacing lost endogenous factors.
Journal ArticleDOI

Neuroprotective Effect of Darbepoetin Alfa, a Novel Recombinant Erythropoietic Protein, in Focal Cerebral Ischemia in Rats

TL;DR: Darbepoetin alfa confers behavioral and histological neuroprotection after focal ischemia in rats and shows improved neuroscores relative to vehicle-treated animals in the 14-day survival period.